Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Opening Session Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Peter Clark, MA, MD, FRCP: A Payer Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Jul

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Opening Session Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Peter Clark, MA, MD, FRCP: A Payer Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

ENDURANCE Trial in Newly Diagnosed Myeloma No Survival Benefit With Indefinite Maintenance Treatment vs 2-Years

Setmelanotide in Patients With Acquired Hypothalamic Obesity

Addition of Sacituzumab Tirumotecan to Pembrolizumab in PD-L1–Positive Advanced NSCLC

Integrated Molecular Analysis Identifies Determinants of Outcomes in TP53-Mutated DLBCL

Ten-Year Follow-up Shows Durable Remissions After CAR T-Cell Therapy for B-Cell Lymphoma